TNYA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TNYA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Tenaya Therapeutics's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Tenaya Therapeutics's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .
Tenaya Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Tenaya Therapeutics's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .
Tenaya Therapeutics's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Tenaya Therapeutics's liquidation value for the three months ended in Mar. 2024 was $95.53 Mil.
The historical data trend for Tenaya Therapeutics's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenaya Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Change In Receivables | - | - | - | - | - |
Tenaya Therapeutics Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Change In Receivables | Get a 7-Day Free Trial | - | - | - | - | - |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenaya Therapeutics (NAS:TNYA) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Tenaya Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 0 | * | 91 |
= |
2. In Ben Graham's calculation of liquidation value, Tenaya Therapeutics's accounts receivable are only considered to be worth 75% of book value:
Tenaya Therapeutics's liquidation value for the quarter that ended in Mar. 2024 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 122.249 | - | 26.719 | + | 0.75 * 0 | + | 0.5 * 0 |
= | 95.53 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Tenaya Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Timothy Hoey | officer: Chief Scientific Officer | C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, 5TH FLR., SOUTH SAN FRANCISCO CA 94080 |
Leone D Patterson | officer: Chief Fin and Bus. Officer | |
Whittemore Tingley | officer: Chief Medical Officer | C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Faraz Ali | director, officer: Chief Executive Officer | C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BLVD., 5TH FLR., SOUTH SAN FRANCISCO Z4 94080 |
David V Goeddel | director, 10 percent owner | C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Column Group Iii Gp, Lp | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Amy L. Burroughs | director | TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447 |
Column Group Iii, Lp | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Column Group Opportunity Iii Gp, Lp | 10 percent owner | 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129 |
Tcg Opportunity Iii Gp, Llc | 10 percent owner | 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129 |
Column Group Opportunity Iii, Lp | 10 percent owner | 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129 |
Deepak Srivastava | director | C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Column Group Iii-a, Lp | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Eli Casdin | director | 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019 |
Casdin Capital, Llc | director | 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019 |
From GuruFocus
By Value_Insider Value_Insider • 11-21-2022
By Value_Insider Value_Insider • 11-16-2022
By sperokesalga sperokesalga • 05-02-2023
By Business Wire Business Wire • 05-03-2022
By Stock market mentor Stock market mentor • 01-09-2023
By GuruFocusNews GuruFocusNews • 07-06-2022
By Value_Insider Value_Insider • 11-28-2022
By Marketwired • 08-02-2023
By Marketwired • 08-31-2023
By Stock market mentor Stock market mentor • 02-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.